Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 795-801

  Brunstein, Flavia ^a   Eggermont, Alexander M M ^a   De Wiel Ambagtsheer, Gisela Aan ^a   Van Tiel, Sandra T ^a   Rens, Joost ^a   Hagen, Timo L M Ten ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Histamine; Liver metastasis; Regional treatment; Sarcomas

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HISTAMINE; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; HISTOLOGY; LIVER; LIVER HISTOLOGY; LIVER INJURY; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MALE; MONOTHERAPY; NONHUMAN; RAT; SOFT TISSUE SARCOMA; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HISTAMINE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MELPHALAN; NEOPLASM TRANSPLANTATION; RATS; SARCOMA;

EID: 33846629479     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9208-4     Document Type: Article

References (20)

1. Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg 1999; 5:65-80.
2. Grover A, Alexander HR Jr. The past decade of experience with isolated hepatic perfusion. Oncologist 2004; 9:653-664.
3. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004; 40:1812-1824.
4. van Etten B, de Vries MR, van Ijken MG, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003; 88:314-319.
5. van Ijken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont AM. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000; 23:449-455.
6. Weinreich DM, Alexander HR. Transarterial perfusion of liver metastases. Semin Oncol 2002; 29:136-144.
7. Lans TE, Bartlett DL, Libutti SK, et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001; 7:784-790.
8. Brunstein F, Hoving S, Seynhaeve AL, et al. Synergistic anti-tumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004; 96:1603-1610.
9. van Etten B, ten Hagen TL, de Vries MR, Ambagtsheer G, Huet T, Eggermont AM. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. Br J Cancer 2002; 86:436-442.
10. Kort WJ, Zondervan PE, Hulsman LO, Weijma IM, Westbroek DL. Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. J Natl Cancer Inst 1984; 72:709-713.
11. Hagen TL, Eggermont AM. Tumor vascular therapy with TNF: critical review on animal models. Methods Mol Med 2004; 98:227-246.
12. de Brauw LM, Marinelli A, van de Velde CJ, Hermans J, Tjaden UR, Erkelens C, de Bruijn EA. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res 1991; 51:1694-1700.
13. Ausman RK. Development of a technique for isolated perfusion of the liver. N Y State J Med 1961; 61:3993-3997.
14. de Vries MR, ten Hagen TL, Marinelli AW, Eggermont AM. Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies. Anticancer Res 2003; 23:1811-1823.
15. de Wilt JH, van Etten B, Verhoef C, Eggermont AM. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am 2004; 84:627-641.
16. van Ijken MG, de Bruijn EA, de Boeck G, ten Hagen TL, van der Sijp JR, Eggermont AM. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 1998; 228:763-770.
17. van Etten B, Brunstein F, van Ijken MG, et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004; 11:598-605.
18. de Vries MR, Borel RI, van de Velde CJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998; 147:107-119.
19. Kuppen PJ, Jonges LE, van de Velde CJ, Vahrmeijer AL, Tollenaar RA, Borel RI, Eggermont AM. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Br J Cancer 1997; 75:1497-1500.
20. Agarwala SS, Hellstrand K, Gehlsen K, Naredi P. Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother 2004; 53:840-841.